MARGINAL ZONE LYMPHOMA (MZL)

This study tests a combination of three drugs (orelabrutinib, rituximab, and possibly lenalidomide) in people with untreated marginal zone lymphoma that has spread. The goal is to see how well the treatment shrinks or eliminates the cancer. About 50 adults will take part, and the…

This study tests a drug called orelabrutinib, taken alone or with another antibody, in people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. About 88 participants will receive the drug for 6 cycles, and doctors wil…

This study is for people with a slow-growing blood cancer called marginal zone lymphoma who haven't had treatment yet. It tests a new approach: a short course of standard chemo followed by a targeted drug (Orelabrutinib) to keep the cancer under control. The goal is to see if thi…

This study tests whether a new combination of drugs (orelabrutinib, zebetuzumab, and lenalidomide) works better than a standard combination (bendamustine and rituximab) for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. About 169 adults aged 18-7…

This study tests a personalized treatment approach for people with untreated marginal zone lymphoma, a slow-growing blood cancer. About 145 participants will receive targeted therapy based on their individual risk score. The goal is to see if this tailored treatment can keep the …

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study is a registry that will follow about 2950 adults in Germany with certain blood cancers (like CLL, DLBCL, and others). Researchers will collect information on the treatments people receive, how their disease progresses, and their quality of life. No new treatments are g…